印度制药行业-英

© Nishith Desai Associates 2023www.nishithdesai.comMUMBAI SILICON VALLEY BANGALORE SINGAPORE NEW DELHI MUNICH / AMSTERDAM NEW YORK GIFT CITYResearchThe Indian Pharmaceutical IndustryRegulatory, Legal and Tax OverviewApril 2023© Nishith Desai Associates 2023concierge@nishithdesai.comResearchThe Indian Pharmaceutical IndustryRegulatory, Legal and Tax OverviewApril 2023© Nishith Desai Associates 2023concierge@nishithdesai.comAsia-PacificMost Innovative Indian Law Firm: 2019, 2017, 2016, 2015, 2014Asia PacificBand 1 for FinTech, Technology Media & Telecoms: 2021Band 1 for Employment, Lifesciences, Tax, TMT: 2021, 2020, 2019, 2018, 2017, 2016, 2015Tier 1 for Private Equity: 2020, 2019, 2018, 2017, 2014Deal of the Year: Private Equity, 2020Asia-Pacific Tier 1 for Data Protection, Dispute, Tax, Investment Funds, Labour & Employment, TMT, Corporate M&A: 2021, 2020, 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012Asia-Pacific Tier 1 for Government & Regulatory, Tax: 2020, 2019, 2018‘Outstanding’ for Technology, Labour & Employment, Private Equity, Regulatory, Tax: 2021, 2020, 2019Global Thought Leader — Vikram Shroff Thought Leaders, India — Nishith Desai, Vaibhav Parikh, Dr. Milind AntaniArbitration Guide, 2021 — Vyapak Desai, Sahil KanugaEminent Lawyer in Sports and Gaming 2021: Tanisha KhannaYoung Lawyer of the Year (Law Firm) 2022: Aarushi JainWinner for Data Compliance and Cybersecurity, Labour and Employment, Media and Entertainment, Pharma and Life Sciences, Taxation (Direct), Taxation (Indirect): 2022Fastest growing M&A Law Firm: 2018Asia Mena Counsel In-House Community Firms Survey: Only Indian Firm for Life Science Practice Sector: 2018 The Indian Pharmaceutical Industry — Regulatory, Legal and Tax Overview © Nishith Desai Associates 2023Provided upon request onlyDisclaimerThis report is a copyright of Nishith Desai Associates. No reader should act on the basis of any statement contained herein without seeking professional advice. The authors and the firm expressly disclaim all and any liability to any person who has read this report, or otherwise, in respect of anything, and of consequences of anything done, or omitted to be done by any such person in reliance upon the contents of this report.ContactFor any help or assistance please email us on concierge@nishithdesai.com or visit us at www.nishithdesai.com.AcknowledgementsDr.Milind Antanimilind.antani@nishithdesai.comDarren Punnen darren.punnen@nishithdesai.comEshika Phadke eshika.phadke@nishithdesai.comVarsha Rajesh varsha.rajesh@nishithdesai.com The Indian Pharmaceutical Industry — Regulatory, Legal and Tax Overview © Nishith Desai Associates 2023Provided upon request onlyContentsExecutive Summary 1Introduction 3India Entry Strategies 5A. Investment Climate in India 5B. Government Production Linked Incentives 6C. India’s Post-Trips Intellectual Property Environment 6D. Form of the Indian Entity 6E. Corporate Governance in